Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Work In Process (2019 - 2025)

Protalix BioTherapeutics has reported Work In Process over the past 8 years, most recently at $9.4 million for Q4 2025.

  • Quarterly results put Work In Process at $9.4 million for Q4 2025, down 16.63% from a year ago — trailing twelve months through Dec 2025 was $9.4 million (down 16.63% YoY), and the annual figure for FY2025 was $9.4 million, down 16.63%.
  • Work In Process for Q4 2025 was $9.4 million at Protalix BioTherapeutics, up from $5.4 million in the prior quarter.
  • Over the last five years, Work In Process for PLX hit a ceiling of $12.3 million in Q3 2024 and a floor of $1.5 million in Q1 2023.
  • Median Work In Process over the past 5 years was $4.4 million (2021), compared with a mean of $6.1 million.
  • Biggest five-year swings in Work In Process: soared 498.11% in 2024 and later crashed 56.29% in 2025.
  • Protalix BioTherapeutics' Work In Process stood at $3.3 million in 2021, then decreased by 17.9% to $2.7 million in 2022, then soared by 238.13% to $9.1 million in 2023, then increased by 24.19% to $11.2 million in 2024, then fell by 16.63% to $9.4 million in 2025.
  • The last three reported values for Work In Process were $9.4 million (Q4 2025), $5.4 million (Q3 2025), and $8.1 million (Q2 2025) per Business Quant data.